Skip to main content
. Author manuscript; available in PMC: 2016 Jul 5.
Published in final edited form as: Adv Exp Med Biol. 2016;916:335–369. doi: 10.1007/978-3-319-30654-4_15

Fig. 4.

Fig. 4

The selective S1P1 antagonist W146 promotes intravasation of bcl-2-overexpressing T-LBL cells in vivo. (a) Schematic drawing of the experimental strategy, (b–g) Confocal images of EGFP-labeled blood vessels (b, e), dsRed2-labeled lymphoma cells (c, f), and the merged images of a vehicle-treated (d; n = 29) and a W146-treated transplanted animal (g; n= 18) demonstrate that W146 treatment promotes intravasation of bcl-2-overexpressing lymphoma cells (arrowheads) in vivo (cf. g to d). Note that W146 treatment also inhibited the in vivo formation of lymphoma cell aggregates (cf. f to c). Scale bar for (b)–(g), 10 mM. (Republished with permission from Elsevier) [89]